Biohaven Ltd. $BHVN Position Boosted by California State Teachers Retirement System

California State Teachers Retirement System grew its holdings in Biohaven Ltd. (NYSE:BHVN) by 56.2% during the first quarter, Holdings Channel.com reports. The firm owned 172,370 shares of the company’s stock after buying an additional 62,009 shares during the period. California State Teachers Retirement System’s holdings in Biohaven were worth $1,458,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Sigma Planning Corp boosted its holdings in shares of Biohaven by 9.2% during the fourth quarter. Sigma Planning Corp now owns 13,613 shares of the company’s stock worth $154,000 after purchasing an additional 1,146 shares during the period. PNC Financial Services Group Inc. lifted its position in Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after buying an additional 1,268 shares in the last quarter. IFP Advisors Inc lifted its position in Biohaven by 55.4% in the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock worth $46,000 after buying an additional 1,450 shares in the last quarter. Rafferty Asset Management LLC boosted its stake in shares of Biohaven by 1.3% during the 2nd quarter. Rafferty Asset Management LLC now owns 121,189 shares of the company’s stock valued at $1,710,000 after buying an additional 1,503 shares during the period. Finally, ProShare Advisors LLC boosted its stake in shares of Biohaven by 10.8% during the 4th quarter. ProShare Advisors LLC now owns 17,138 shares of the company’s stock valued at $193,000 after buying an additional 1,669 shares during the period. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven Stock Up 3.4%

BHVN stock opened at $14.88 on Friday. The firm has a market cap of $2.25 billion, a PE ratio of -3.21 and a beta of 1.26. Biohaven Ltd. has a 1 year low of $7.48 and a 1 year high of $18.57. The company has a fifty day simple moving average of $14.24 and a 200 day simple moving average of $11.66. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Sell-side analysts anticipate that Biohaven Ltd. will post -3.1 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Morgan Stanley upped their price target on shares of Biohaven from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a research report on Wednesday, May 27th. Bank of America reaffirmed an “underperform” rating and set a $11.00 price target (down from $12.00) on shares of Biohaven in a research note on Monday, June 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biohaven in a report on Tuesday, June 2nd. Finally, Wall Street Zen raised Biohaven from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.